Charles Piller on Muck Rack

Charles Piller

Verified
United States
As seen in: Science Magazine, The New York Times, Daily Mail, Fox News, The Mail on Sunday, Los Angeles Times, PBS, PBS NewsHour, Scientific American, Substack, The Boston Globe and
Investigative reporter @sciencemagazine. Author of "Doctored" cpiller@charlespiller.com - Signal: cpiller.01 - open DMs.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Charles

Contact Charles, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Charles Piller’s Biography

Read Full Bio →

Charles Piller, STAT’s West Coast editor, writes watchdog reports and in-depth projects from his base in the San Francisco Bay Area. He previously worked as an investigative journalist for The Sacramento Bee and the Los Angeles Times, and has reported on public health, science, and technology from Africa, Asia, Europe, and Central America. Charles has won numerous journalism awards, has authored two investigative books about science, and has reported extensively on prison conditions and bridge …

Articles

Alzheimer’s drug developers accuse clinical trial sites of faking data

|
By Charles Piller 
| Science Magazine
In 2023, the drug developer T3D Therapeutics glimpsed a breakthrough after a decade of research on a novel compound to treat Alzheimer’s disease. A clinical trial for its drug, code-named T3D-959, initially seemed to support the company’s belief that the pill stimulates the brain’s ability to process sugar and could reverse cognitive decline in the neurodegenerative condition. But before it trumpeted the good news, the small company took a closer look at detailed data for each participant.
Open in Who Shared Issue with article?

Misconduct sleuth wins $2.63 million from major cancer institute in $15 million settlement

|
By Charles Piller 
| Science Magazine
Yesterday the Department of Justice (DOJ) announced a $15 million settlement by the Dana-Farber Cancer Institute with the U.S. government and Sholto David, the research integrity sleuth who had spotted duplicated or misrepresented images in papers the center’s scientists cited in federal grant applications.
Open in Who Shared Issue with article?

As his fraud trial looms, Alzheimer’s scientist exonerated by his university-sort of

|
By Charles Piller 
| Science Magazine
Next week, the U.S. Department of Justice (DOJ) is scheduled to begin trying a former City University of New York (CUNY) scientist for fraud related to his work on a failed drug for Alzheimer’s disease. But according to a 30 May letter from the school made public in court records Tuesday, CUNY has officially concluded that the researcher, Hoau-Yan Wang, did not engage in scientific misconduct. The letter is rife with ambiguity, however.
Open in Who Shared Issue with article?
See all 188 licensed articles (278 Total)

Actions

Share this page

Get in touch with Charles

Contact Charles, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified